PHE's Goldman in Fortune: Innovative Drugs Deserve Innovative Pricing
PHE cofounder Dana Goldman, along with coauthor David Agus, contribute a new commentary for Fortune.com. Discussing the significance of Kymriah, the first gene therapy for cancer to achieve FDA approval, Goldman and Agus make the point that although the promise and pricing of the new drug is grabbing all the headlines, the accompanying risk sharing agreement between CMS and Novartis is even more significant.
To read the complete article, please click here.
Led by Caroline Huber, Associate Director of Policy and Economics, a surprising new study was recently published in The Journal of Infectious Diseases, estimating the overlooked social, economic and health impacts of the 2013-2016 West Africa Ebola crisis.